Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid
Journal of Alzheimer's Disease · 2023
DOI: 10.3233/jad-221266 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2023. Verfasst von Dina Rodrigues Martins und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Department, Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium. Hauptthemen laut MEDLINE: Tauopathies, Alzheimer Disease. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
Clearance of tau seeds by immunization with tau antibodies is currently evaluated as therapeutic strategy to block the spreading of tau pathology in Alzheimer’s disease and other tauopathies. Preclinical evaluation of passive immunotherapy is performed in different cellular culture systems and in wild-type and human tau transgenic mouse models. Depending on the preclinical model used, tau seeds or induced aggregates can either be of mouse, human or mixed origin.
Objective
We aimed to develop human and mouse tau-specific antibodies to discriminate between the endogenous tau and the introduced form in preclinical models.
Methods
Using hybridoma technology, we developed human and mouse tau-specific antibodies that were then used to develop several assays to specifically detect mouse tau.
Results
Four antibodies, mTau3, mTau5, mTau8, and mTau9, with a high degree of specificity for mouse tau were identified. Additionally, their potential application in highly sensitive immunoassays to measure tau in mouse brain homogenate and cerebrospinal fluid is illustrated, as well as their application for specific endogenous mouse tau aggregation detection.
Conclusion
The antibodies reported here can be very important tools to better interpret the results obtained from different model systems as well as to study the role of endogenous tau in tau aggregation and pathology observed in the diverse mouse models available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Department, Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
- Biologics Research, Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Zitieren
APA
Rodrigues Martins, D., Vandermeeren, M., Van Kolen, K., Brepoels, E., Borgers, M., Wintmolders, C., Delay, C., Bottelbergs, A., Mercken, M., & Theunis, C. (2023). Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-221266
Vancouver
Rodrigues Martins D, Vandermeeren M, Van Kolen K, Brepoels E, Borgers M, Wintmolders C, et al. Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid. Journal of Alzheimer's Disease. 2023. doi:10.3233/jad-221266
BibTeX
@article{RodriguesMartins2023,
author = {Rodrigues Martins, Dina and Vandermeeren, Marc and Van Kolen, Kristof and Brepoels, Eddy and Borgers, Marianne and Wintmolders, Cindy and Delay, Charlotte and Bottelbergs, Astrid and Mercken, Marc and Theunis, Clara},
title = {Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid},
journal = {Journal of Alzheimer's Disease},
year = {2023},
doi = {10.3233/jad-221266}
}
EUVIMED